Related Experiment Videos
Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of
Abstract:
Genetic and biochemical evidence suggests that the Ras protooncogene product regulates the activation of the Raf kinase pathway, leading to the proposal that Raf is a direct mitogenic effector of activated Ras. Here we report the use of a novel competition assay to measure in vitro the relative affinity of the c-Raf-1 regulatory region for Ras-GTP, Ras-GDP, and 10 oncogenic and effector mutant Ras proteins. c-Raf-1 associates with normal Ras and the oncogenic V12 and L61 forms of Ras with equal affinity. The moderately transforming mutant Ras[E30K31] also bound to the c-Raf-1 regulatory region with normal affinity. Transformation-defective Ras effector mutants Ras[N33], Ras[S35], and Ras[N38] bound poorly. In contrast, the transformation defective Ras[G26I27] and Ras[E45] mutants bound to the c-Raf-1 regulatory region with nearly wild-type affinity. A stable, high-affinity Ras-binding region of c-Raf-1 was mapped to a 99-amino-acid subfragment of the first 257 residues. The smallest Ras-binding region identified consisted of N-terminal residues 51 to 131, although stable expression of the domain and high-affinity binding were improved by the presence of residues 132 to 149. Deletion of the Raf zinc finger region did not reduce Ras-binding affinity, while removal of the first 50 amino acids greatly increased affinity. Phosphorylation of Raf[1-149] by protein kinase A on serine 43 resulted in significant inhibiton of Ras binding. demonstrating that the mechanism of cyclic AMP downregulation results through structural changes occurring exclusively in this small Ras-binding domain.
Insights
Researchers investigated the interaction between Ras proteins and the c-Raf-1 regulatory region using a novel competition assay. They identified specific Ras mutants that bind poorly, revealing key insights into Ras-Raf signaling pathways and potential therapeutic targets.
Area of Science:
- Molecular Biology
- Cell Signaling
- Oncogenesis
Background:
- Ras protooncogene product is implicated in regulating the Raf kinase pathway.
- Raf is proposed as a direct mitogenic effector of activated Ras.
- Understanding Ras-Raf interactions is crucial for cancer research.
Purpose of the Study:
- To quantify the binding affinity of the c-Raf-1 regulatory region to various Ras-GTP, Ras-GDP, and Ras mutants.
- To identify the specific domains within c-Raf-1 responsible for Ras binding.
- To elucidate the impact of Ras mutations on c-Raf-1 association.
Main Methods:
- Utilized a novel competition assay to measure in vitro binding affinities.
- Tested interactions between c-Raf-1 regulatory region and 10 oncogenic and effector mutant Ras proteins.
- Mapped the Ras-binding region within c-Raf-1 using deletion analysis.
Main Results:
- c-Raf-1 exhibited equal affinity for normal Ras, Ras-GTP, and oncogenic Ras mutants (V12, L61).
- Transformation-defective Ras effector mutants (N33, S35, N38) showed poor binding.
- A minimal Ras-binding domain was mapped to N-terminal residues 51-131 of c-Raf-1.
- Phosphorylation at serine 43 significantly inhibited Ras binding.
Conclusions:
- Ras binding to c-Raf-1 is dependent on specific effector domain residues.
- The N-terminal region of c-Raf-1 (residues 51-149) is critical for high-affinity Ras interaction.
- Phosphorylation of c-Raf-1 regulates its interaction with Ras, impacting downstream signaling.